cilostazol has been researched along with Arteriosclerosis in 14 studies
Arteriosclerosis: Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This paper represents a review, by experts, of current opinion and information on intermittent claudication (IC) and the role that cilostazol plays in its treatment." | 8.82 | The role of cilostazol in the treatment of intermittent claudication. ( Barnett, AH; Bradbury, AW; Brittenden, J; Crichton, B; Donnelly, R; Homer-Vanniasinkam, S; Mikhailidis, DP; Stansby, G, 2004) |
| "Cilostazol is a new phosphodiesterase inhibitor that suppresses platelet aggregation and also acts as a direct arterial vasodilator." | 6.69 | Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. ( Cutler, BS; Dawson, DL; Meissner, MH; Strandness, DE, 1998) |
| "This paper represents a review, by experts, of current opinion and information on intermittent claudication (IC) and the role that cilostazol plays in its treatment." | 4.82 | The role of cilostazol in the treatment of intermittent claudication. ( Barnett, AH; Bradbury, AW; Brittenden, J; Crichton, B; Donnelly, R; Homer-Vanniasinkam, S; Mikhailidis, DP; Stansby, G, 2004) |
| "Cilostazol is an anti-thrombotic and vasodilating agent, reported to have both anti-thrombotic and cerebral vasodilating effects." | 2.71 | Effects of cilostazol on serum lipid concentrations and plasma fatty acid composition in type 2 diabetic patients with peripheral vascular disease. ( Hamazaki, T; Johkaji, H; Kobayashi, M; Minami, S; Nakamura, N; Okomura, K; Osawa, H; Satoh, A; Sawazaki, S; Urakaze, M; Yamabe, H; Yamazaki, K, 2003) |
| "Cilostazol is a new phosphodiesterase inhibitor that suppresses platelet aggregation and also acts as a direct arterial vasodilator." | 2.69 | Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. ( Cutler, BS; Dawson, DL; Meissner, MH; Strandness, DE, 1998) |
| "The key areas of treatment focus on smoking cessation, exercise rehabilitation, with supervised therapy if possible, cardiovascular risk prevention with antiplatelet drugs, statins and angiotensin converting enzymes, and correction of atherosclerotic risk factors with well-defined targets (LDL less than 1g/L, HDL greater than 0." | 2.45 | [Peripheral arterial disease with lower limb claudication: Medical treatment]. ( Bui, HT; Hadj Henni, A; Journet, J; Long, A, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 10 (71.43) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Koga, Y | 1 |
| Kihara, Y | 1 |
| Okada, M | 1 |
| Inoue, Y | 1 |
| Tochizawa, S | 1 |
| Toga, K | 1 |
| Tachibana, K | 1 |
| Kimura, Y | 1 |
| Nishi, T | 1 |
| Hidaka, H | 1 |
| Long, A | 1 |
| Bui, HT | 1 |
| Journet, J | 1 |
| Hadj Henni, A | 1 |
| Grouse, JR | 1 |
| Allan, MC | 1 |
| Elam, MB | 1 |
| Nakamura, N | 1 |
| Hamazaki, T | 1 |
| Johkaji, H | 1 |
| Minami, S | 1 |
| Yamazaki, K | 1 |
| Satoh, A | 1 |
| Sawazaki, S | 1 |
| Urakaze, M | 1 |
| Kobayashi, M | 1 |
| Osawa, H | 1 |
| Yamabe, H | 1 |
| Okomura, K | 1 |
| Shin, HK | 1 |
| Kim, YK | 1 |
| Kim, KY | 1 |
| Lee, JH | 2 |
| Hong, KW | 2 |
| Takahashi, K | 1 |
| Iijima, K | 1 |
| Nagasaki, M | 1 |
| Torii, I | 1 |
| Yamaguchi, S | 1 |
| Kobayashi, S | 1 |
| Barnett, AH | 1 |
| Bradbury, AW | 1 |
| Brittenden, J | 1 |
| Crichton, B | 1 |
| Donnelly, R | 1 |
| Homer-Vanniasinkam, S | 1 |
| Mikhailidis, DP | 1 |
| Stansby, G | 1 |
| Mitsuhashi, N | 1 |
| Tanaka, Y | 1 |
| Kubo, S | 1 |
| Ogawa, S | 1 |
| Hayashi, C | 1 |
| Uchino, H | 1 |
| Shimizu, T | 1 |
| Watada, H | 1 |
| Kawasumi, M | 1 |
| Onuma, T | 1 |
| Kawamori, R | 1 |
| Oh, GT | 1 |
| Park, SY | 1 |
| Choi, JH | 1 |
| Park, JG | 1 |
| Kim, CD | 1 |
| Lee, WS | 1 |
| Rhim, BY | 1 |
| Shin, YW | 1 |
| Dawson, DL | 1 |
| Cutler, BS | 1 |
| Meissner, MH | 1 |
| Strandness, DE | 1 |
| Priollet, P | 1 |
| Yang, R | 1 |
| Powell-Braxton, L | 1 |
| Ogaoawara, AK | 1 |
| Dybdal, N | 1 |
| Bunting, S | 1 |
| Ohneda, O | 1 |
| Jin, H | 1 |
| Hayashi, S | 1 |
| Morishita, R | 1 |
| Matsushita, H | 1 |
| Nakagami, H | 1 |
| Taniyama, Y | 1 |
| Nakamura, T | 1 |
| Aoki, M | 1 |
| Yamamoto, K | 1 |
| Higaki, J | 1 |
| Ogihara, T | 1 |
| Regensteiner, JG | 1 |
| Hiatt, WR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of Cilostazol in Combination With L-Carnitine in Subjects With Intermittent Claudication[NCT00822172] | Phase 4 | 164 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 1.065 |
| Cilostazol + Placebo | 0.896 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 1.001 |
| Cilostazol + Placebo | 0.815 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 0.241 |
| Cilostazol + Placebo | 0.134 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 0.267 |
| Cilostazol + Placebo | 0.145 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 0.166 |
| Cilostazol + Placebo | 0.139 |
Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | score on a scale (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 13.20 |
| Cilostazol + Placebo | 6.57 |
Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 90
| Intervention | score on a scale (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 12.98 |
| Cilostazol + Placebo | 10.01 |
5 reviews available for cilostazol and Arteriosclerosis
| Article | Year |
|---|---|
[Peripheral arterial disease with lower limb claudication: Medical treatment].
Topics: Aged; Antihypertensive Agents; Arteriosclerosis; Cilostazol; Comorbidity; Diabetes Complications; Dr | 2009 |
Clinical manifestation of atherosclerotic peripheral arterial disease and the role of cilostazol in treatment of intermittent claudication.
Topics: Arteriosclerosis; Cholesterol, HDL; Cilostazol; Clinical Trials as Topic; Humans; Hypolipidemic Agen | 2002 |
The role of cilostazol in the treatment of intermittent claudication.
Topics: Algorithms; Arteriosclerosis; Cilostazol; Clinical Trials as Topic; Humans; Intermittent Claudicatio | 2004 |
[Arteriopathy of the lower limbs: toward a global medical care].
Topics: Angiography; Arterial Occlusive Diseases; Arteriosclerosis; Cilostazol; Clinical Trials as Topic; Cl | 1999 |
Current medical therapies for patients with peripheral arterial disease: a critical review.
Topics: Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis; Cardiovascular Diseases; Cilostazol; Dia | 2002 |
3 trials available for cilostazol and Arteriosclerosis
| Article | Year |
|---|---|
Effects of cilostazol on serum lipid concentrations and plasma fatty acid composition in type 2 diabetic patients with peripheral vascular disease.
Topics: Aged; Apolipoproteins; Arteriosclerosis; Blood Glucose; Cilostazol; Diabetes Mellitus, Type 2; Fasti | 2003 |
Effect of cilostazol, a phosphodiesterase inhibitor, on carotid IMT in Japanese type 2 diabetic patients.
Topics: Aged; Arteriosclerosis; Blood Pressure; Carotid Arteries; Cholesterol; Cilostazol; Diabetes Mellitus | 2004 |
Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial.
Topics: Adult; Aged; Arteriosclerosis; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cilostazol; Double-B | 1998 |
6 other studies available for cilostazol and Arteriosclerosis
| Article | Year |
|---|---|
2(1H)-quinolinone derivatives as novel anti-arteriostenotic agents showing anti-thrombotic and anti-hyperplastic activities.
Topics: Animals; Arteriosclerosis; Cilostazol; Hyperplasia; Platelet Aggregation Inhibitors; Quinolines; Qui | 1998 |
Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol.
Topics: Adult; Apoptosis; Arteriosclerosis; Cells, Cultured; Chylomicron Remnants; Chylomicrons; Cilostazol; | 2004 |
Deterioration of vascular dementia caused by recurrent multiple small emboli from thoracic aortic atheroma.
Topics: Aged; Aorta, Thoracic; Arteriosclerosis; Cilostazol; Dementia, Vascular; Disease Progression; Emboli | 2004 |
Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-alpha formation in low-density lipoprotein receptor-null mice fed high cholesterol.
Topics: Animals; Arteriosclerosis; Cell Line; Cholesterol, Dietary; Cilostazol; Diet, Atherogenic; Dose-Resp | 2005 |
Hypertension and endothelial dysfunction in apolipoprotein E knockout mice.
Topics: Age Factors; Animals; Apolipoproteins E; Arteriosclerosis; Cholesterol; Cilostazol; Endothelium, Vas | 1999 |
Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Aorta; Apoptosis; Arteriosclerosis; Blotting, Western; Cell | 2000 |